Research Article

An Oral Vaccine Against NMDAR1 with Efficacy in Experimental Stroke and Epilepsy

Science  25 Feb 2000:
Vol. 287, Issue 5457, pp. 1453-1460
DOI: 10.1126/science.287.5457.1453

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Abstract

The brain is generally considered immunoprivileged, although increasing examples of immunological responses to brain antigens, neuronal expression of major histocompatibility class I genes, and neurological autoimmunity have been recognized. An adeno-associated virus (AAV) vaccine generated autoantibodies that targeted a specific brain protein, the NR1 subunit of theN-methyl-d-aspartate (NMDA) receptor. After peroral administration of the AAV vaccine, transgene expression persisted for at least 5 months and was associated with a robust humoral response in the absence of a significant cell-mediated response. This single-dose vaccine was associated with strong anti-epileptic and neuroprotective activity in rats for both a kainate-induced seizure model and also a middle cerebral artery occlusion stroke model at 1 to 5 months following vaccination. Thus, a vaccination strategy targeting brain proteins is feasible and may have therapeutic potential for neurological disorders.

  • * To whom correspondence should be addressed. E-mail: matthew.during{at}mail.tju.edu

View Full Text

Cited By...